Hcp & Patient Consumer Channel Partners
— What, Why, How
HCP/DTC Partner Ecosystem — Led & Scaled
- HCP Vendor Matrix (endemic + data)
A one-page view of the platforms that reach verified clinicians and unlock prescriber/clinical data—what each does, strengths, watch-outs, and exactly how the channel is run for outcomes. This is my bread-and-butter toolkit—drawn from a short list of top vendor partners I’ve personally worked with to put their data to work. (License to optimize, not to kill budgets.)
Vendor | Category | What they do (reach/data) | What they do well (proof) | Watch-outs | How I leverage (my playbook) |
|---|---|---|---|---|---|
Doximity | HCP social + endemic media | NPI-verified HCP network, endemic feed and email; precision specialty targeting for clinical content. | High specialty granularity and engagement; native clinical formats that feel educational. | Frequency/overlap with other endemic networks; keep creative succinct and MLR-tight. | Build NPI lists, map to segments, run DocNews/sponsored content; connect exposure to CRM and outcomes to optimize. |
Medscape / WebMD Ignite (incl. PulsePoint) | HCP network + programmatic extension | Large endemic HCP inventory with programmatic extension across the open web and multiple regions. | Scale across endemic + offsite; rich education/CME inventory that aligns with clinical learning. | Premium CPMs; deduplicate vs. Doximity/other endemic channels. | Use endemic for disease education and Extend for incremental scale; suppress exposed HCPs; enforce MMM/MTA-ready tags. |
IQVIA (OneKey, Xponent, Digital) | Identity + prescribing + audiences | OneKey HCP identity graph, Xponent prescribing data, and permissioned HCP/consumer audiences. | Reliable prescriber behavior and sub-national granularity for tiering/whitespace strategies. | Separate targeting vs. outcome data to avoid closed-loop bias; strict governance. | Use Xponent to define tiers/whitespace; activate segments; measure with outcomes partners; feed results into MMM/MTA. |
DeepIntent | Health DSP (HCP + DTC) | DSP built for healthcare with verified HCP and privacy-safe patient profiles; channels include display, video, CTV. | Strong health signals and broad channel mix; robust HCP verification features. | Validate data provenance; curate site/app lists; maintain regulatory guardrails. | Use as neutral activator; onboard IQVIA/Komodo segments; enforce IVT caps and brand safety; read outcomes for weekly budget pivots. |
Swoop | Privacy-safe patient audiences | De-identified, privacy-safe patient segments and predictive audiences; partnerships with patient communities. | Clear privacy narrative and state-level guardrails; strong for rare/chronic audience discovery. | Manage cohort sizes and re-identification risk; tight MLR governance for sensitive conditions. | Use where claims are too risky; pair with education/KOL content; outcome-read with an approved measurement partner. |
Doceree | HCP programmatic | Programmatic HCP media across verified medical properties with identity/context-aware placements. | Efficient incremental reach beyond walled gardens; good contextual adjacency to journals and medical news. | Quality dispersion; enforce frequency controls and domain curation. | Run context+identity plays around journal content; throttle frequency; close loop with first-party analytics. |
Phreesia Life Sciences | Point-of-care patient activation | Media pre/during/post visit via patient intake workflows and care-episode triggers. | High-intent moments tied to real visits; useful for starts and adherence. | Inventory fragmentation; strict MLR timelines for creative. | Deploy for adherence/start programs; align creative to visit reason; measure NBRx/ABRx with outcomes partners. |
Komodo Health | RWD for audience + insights | Large-scale patient journeys and HCP treatment patterns for discovery, gaps, and geo targeting. | Excellent for identifying underserved geos and care pathways to inform audience design. | Licensing complexity and governance; ensure proper data-use controls. | Build patient/HCP propensity models; push segments to DSPs; validate with field teams and performance reads. |
Flatiron Health | Oncology EHR-derived RWD | Deep oncology EHR datasets with tumor-specific variables and longitudinal journeys. | Rich tumor-level insights that sharpen segmentation and KOL mapping. | Not a media network; use as insight spine vs. direct activation. | Refine tumor cohorts and KOL maps; inform content strategy and HCP tiering rules elsewhere. |
Aptitude Health | Oncology KOL & market intelligence | Global KOL network and insight programs on treatment patterns and decision drivers. | First-hand expert synthesis post-congress; fast signal on practice change. | Not an ad platform—feed outputs into audience/content strategy. | Update clinical narratives, objection handling, and HCP tiering quarterly; align with medical on claims. |
OpenEvidence | Clinical evidence engine | AI-driven evidence aggregation and clinician-friendly summaries for compliant content. | Rapid synthesis of peer-reviewed sources; supports unbranded education and MLR velocity. | Ensure medical/legal review steps; not a media channel. | Arm content/KOL briefs with the latest evidence; increase engagement quality across endemic placements. |
Veeva Crossix | Measurement & optimization | Outcomes measurement connecting media exposure to starts, adherence, and patient conversions. | Trusted outcomes read across HCP and DTC; informs budget reallocation. | Attribution nuance (cohort size, latency); define guardrails up front. | Standardize on outcomes measurement; feed MMM/MTA; pivot budgets weekly by region and channel to lift qualified reach & ROAS. |
- Patient/DTC Channels Matrix (awareness → action)
A one-page view of the consumer platforms that build condition awareness and drive next steps (education, screeners, find-a-doc), with playbook notes for compliant activation. Same playbook energy: proven partners I’ve deployed, tuned, and measured—quietly effective
Vendor | Category
| What they do (reach/data) | What they do well (strengths) | ||
|---|---|---|---|---|---|
Why they matter
Right audience, right intensity
Prescribing behavior and real-world data guide who to prioritize and how hard to lean in (tiers/deciles/whitespace) at national and sub-national levels.
Oncology depth, real clinical relevance
Tumor-type insights and KOL signals sharpen micro-segments and messaging so endemic buys land with clinical credibility.
Regional budget agility
RWD surfaces underserved geographies and care gaps; spend pivots weekly by region and channel to expand qualified reach and improve ROAS—without breaking compliance.
How they’re used
- (operating rhythm)
1. Identity & consent spine
OneKey/NPI for HCP identity matching; consent modes for consumer. Every activation and measurement step ties back to this spine.
2. Audience design
Start with prescriber tiers and patient journeys → translate to platform segments (e.g., Doximity specialties, Medscape Extend filters, health-safe programmatic IDs).
3. Compliance up front
HIPAA/OPDP guardrails, de-identification rules, and state-level restrictions are embedded at the brief stage—not after launch.
4. Moment-of-care orchestration
When intent peaks around a visit, point-of-care partners (e.g., intake or in-office media) reinforce starts/adherence.
5. Measurement truth set
Outcomes partners connect exposure to starts and adherence. Results feed MMM/MTA so budgets can be re-allocated weekly by region and channel.
6. Content intelligence
Evidence engines and KOL insights keep claims and messaging current, improving engagement quality and MLR velocity.
Governance & ROI loop
- (how results are delivered)
- Identity & consent: enforce NPI match for HCP; consent modes for consumer journeys.
- Compliance ribbon: OPDP/HIPAA/GDPR built into briefs, naming/UTM standards, and site/app allow-lists.
- Point-of-care reinforcement: align creative with visit reason for starts/adherence.
- Outcomes measurement: standardized cohort windows and thresholds; results feed MMM/MTA; budgets pivot weekly by region/channel.
- Content currency: evidence/KOL inputs keep claims and creative fresh and MLR-ready.
Vendor Contract Management — how agreements protect ROI
I manage contracts end-to-end to protect compliance and performance: precise scope and outcome KPIs; data-use terms (BAA/DPA, permitted uses, de-identification); SLAs (latency, uptime, IVT thresholds, viewability/attention, brand safety, blocklists); integrations (GA4/Veeva/CRM, naming/UTM taxonomies); measurement plans (methodology, read windows, cohort thresholds, make-goods); pricing controls (rate cards, overage terms); change control and exit/transition plans. I also leverage close vendor relationships to negotiate best-in-market proposals and unlock added tech features on the account—then oversee integrations and vendor management across global campaigns.
Quarterly business reviews run on scorecards tied to ROI, regional performance, and compliance audits—enabling confident renewals and rapid, data-driven spend pivots.
Proof bar
Global dashboards live in production; reporting lag reduced by double digits.
Budget pivots executed weekly by region/channel off outcomes reads.
Oncology microsegments and KOL-aligned messaging increased qualified HCP engagement and patient follow-through.
FAQs
White-label or visible to client?
Either—I’ll slot into your PMO, tools, and cadence.
Regulatory fit?
OPDP/APLB-aligned patterns; HIPAA/GDPR consent and clean-room options.
Handover?
Artifacts delivered in your formats (Confluence/Notion/Slides; repo for specs).